Page last updated: 2024-11-12

adenanthin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

adenanthin: inhibits both peroxiredoxin I and II; isolated from Rabdosia adenantha; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Rabdosiagenus[no description available]LamiaceaeThe mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]

Cross-References

ID SourceID
PubMed CID15011073
CHEMBL ID513653
MeSH IDM000608635

Synonyms (13)

Synonym
111917-59-0
CHEMBL513653
adenanthin
adenanthin a
[(1r,2r,4r,6s,8s,9s,10s,11s,13s)-2,8-diacetyloxy-6-hydroxy-5,5,9-trimethyl-14-methylidene-3,15-dioxo-11-tetracyclo[11.2.1.01,10.04,9]hexadecanyl] acetate
AKOS032962103
adenanthina
adenanthin-a
(1s,3s,4ar,6r,6ar,9s,11s,11as,11bs)-3-hydroxy-4,4,11b-trimethyl-8-methylene-5,7-dioxotetradecahydro-6a,9-methanocyclohepta[a]naphthalene-1,6,11-triyl triacetate
(1,3,7,11)-1,7,11-tris(acetyloxy)-3-hydroxykaur-16-ene-6,15-dione
CS-0023382
HY-N2819
FS-10145

Research Excerpts

Actions

ExcerptReferenceRelevance
"Adenanthin was used to inhibit the thioredoxin-dependent antioxidant defense system."( Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents.
Bajor, M; Domagala, A; Firczuk, M; Gaj, P; Golab, J; Graczyk-Jarzynka, A; Kniotek, M; Muchowicz, A; O'Leary, PC; Siedlecki, P; Siernicka, M; Trzeciak, L; Zagozdzon, A; Zagozdzon, R; Zych, AO, 2018
)
1.2
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1127070Cytotoxicity against human SW480 cells assessed as growth inhibition after 48 hrs by MTS assay2014Journal of natural products, Apr-25, Volume: 77, Issue:4
Cytotoxic ent-kaurane diterpenoids from Isodon wikstroemioides.
AID383204Cytotoxicity against human A549 cells2008Journal of natural products, Apr, Volume: 71, Issue:4
ent-Kaurane Diterpenoids from Isodon nervosus.
AID1127068Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTS assay2014Journal of natural products, Apr-25, Volume: 77, Issue:4
Cytotoxic ent-kaurane diterpenoids from Isodon wikstroemioides.
AID383205Cytotoxicity against human HepG2 cells2008Journal of natural products, Apr, Volume: 71, Issue:4
ent-Kaurane Diterpenoids from Isodon nervosus.
AID1127066Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by MTS assay2014Journal of natural products, Apr-25, Volume: 77, Issue:4
Cytotoxic ent-kaurane diterpenoids from Isodon wikstroemioides.
AID1127071Inhibition of nitric oxide production in LPS-stimulated mouse RAW264.7 cells after 18 hrs by griess reagent based plate reader analysis2014Journal of natural products, Apr-25, Volume: 77, Issue:4
Cytotoxic ent-kaurane diterpenoids from Isodon wikstroemioides.
AID383203Cytotoxicity against human K562 cells2008Journal of natural products, Apr, Volume: 71, Issue:4
ent-Kaurane Diterpenoids from Isodon nervosus.
AID1127069Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTS assay2014Journal of natural products, Apr-25, Volume: 77, Issue:4
Cytotoxic ent-kaurane diterpenoids from Isodon wikstroemioides.
AID1127067Cytotoxicity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTS assay2014Journal of natural products, Apr-25, Volume: 77, Issue:4
Cytotoxic ent-kaurane diterpenoids from Isodon wikstroemioides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (6.67)29.6817
2010's12 (80.00)24.3611
2020's2 (13.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.32 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.86 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]